Today announced the initiation of a Stage 2 clinical study with ANG1005.

Scientific sites. Study endpoints include objective response price, progression-free survival, overall survival and duration of response, in addition to basic safety and tolerability. To find out more about the analysis please make reference to.. Angiochem commences ANG1005 Phase 2 clinical study in HER2+ breast cancer patients with brain metastases Angiochem, a clinical stage biotechnology organization developing drugs that are uniquely capable of crossing the blood-human brain barrier , today announced the initiation of a Stage 2 clinical study with ANG1005, a novel paclitaxel-peptide drug conjugate, in HER2+ breasts cancer patients. This research is designed to evaluate the anti-tumor activity of ANG1005 as a fresh approach to treating HER2+ breast cancer patients with progressive or recurrent brain metastases.The Associated Press/Washington Post: Movement OBSERVED IN 'Fiscal Cliff' Talks As Boehner Gives Revenue Boost In exchange, Boehner is requesting $1 trillion in spending cuts from government advantage applications like Medicare. Those cuts would defer the majority of a painful group of across-the-plank spending cuts arranged to slash many domestic applications and the Pentagon spending budget by 8-9 %, beginning in January .